Everything Bentrio, on one page.
Pick a tile and it opens. Every document here is free to read, no sign-in needed.
Meet Bentrio
What it is, how it works and why it matters.
- Open to readThe essentialsProduct factsheetSpecifications, dosage, ingredients, packaging and product codes on a single page.PDF · Version 3Open(opens in a new tab)
- Open to readThe one-minute readKey benefits one-pagerIndication, key benefits and market status at a glance.PDFOpen(opens in a new tab)
- Open to readThe full storyInformation deckThe complete product presentation for partner discussions.PDFOpen(opens in a new tab)
See the proof
Peer-reviewed, published studies. Free for everyone to read.
- Open to readThe headline trialAM-301 versus saline spray in seasonal allergic rhinitisRandomized clinical trial with 100 patients over two weeks. Significantly lower nasal symptom scores than saline (p = .013) and better quality of life.PDF · Allergy 2024Open(opens in a new tab)
- Open to readGrass pollenBarrier-forming nasal spray under grass pollen exposureRandomized, open-label crossover trial in an allergen challenge chamber with 36 adults. Non-inferior to an established barrier product (HPMC).PDF · Int Arch Allergy 2023Open(opens in a new tab)
- Open to readHouse dust mitesBarrier-forming nasal spray reduces house dust mite symptomsRandomized, open-label crossover study with 37 adults with perennial allergic rhinitis. Significant symptom reduction (p = 0.0085), with protection observed for up to 180 minutes.PDF · Clin Transl Allergy 2023Open(opens in a new tab)
- Open to readStaying powerNasal residence time and rheology of the gel emulsion sprayThe spray reverts to a gel after application and remains on the nasal mucosa for up to 210 minutes in healthy volunteers.PDF · Drug Dev Ind Pharm 2023Open(opens in a new tab)
- Open to readIn the labDrug-free nasal spray as a barrier against SARS-CoV-2Laboratory (in vitro) study on human nasal airway epithelia: no toxic effects, and viral titer reduced by up to 99% with prophylactic application.PDF · Int J Mol Sci 2022Open(opens in a new tab)
Work with us
Claims and paperwork for distribution partners.
- Open to readWhat we can sayClaims overview: USA and EuropeSummary of the claims cleared for the USA (510(k)) and Europe.PresentationOpen(opens in a new tab)
- Open to readBefore we talkConfidentiality agreement (two-way)Mutual confidentiality agreement template, form FRM-111.PDF · V3.0Open(opens in a new tab)